Skip to content
Parakho

Suven Life Sciences Ltd

NSE SUVENBSE 530239

Q1 FY27, unaudited

Revenue
₹3.57 Cr
Profit after tax
₹-127.61 Cr

As filed with the exchange, consolidated basis.

Statement of profit and loss

Figures in ₹ crore, reproduced from the results data files the company filed with NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.

Statement of profit and loss, consolidated basis
₹ croreQ1 FY27vs a year agoFY26
Revenue from operations3.57—7.11
Other income7.52—13.93
Total income11.09—21.04
Employee benefit expense7.28—24.15
Finance costs0.48—0.16
Depreciation & amortisation2.16—5.61
Total expenses138.70—297.39
Profit before tax-127.61—-276.34
Tax expense0.00—0.00
Profit after tax-127.61—-276.34
Total comprehensive income-127.65—-277.53
Earnings per share
Earnings per share, basic₹-4.84₹-12.13
Earnings per share, diluted₹-4.84₹-12.13

Q1 FY27 — unaudited, from the company’s filing with NSE. Source

FY26 — unaudited, from the company’s filing with NSE. Source

Why the dash

Parakho has not ingested this company’s year-ago quarter, so the change column stays empty. A dash means we do not hold the figure — never that it is zero.

Earnings call

Suven Life Sciences Ltd has not filed a concall transcript in the last 4 quarters.

Filings

12 shown · 43 published by the exchange

BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.

Page generated from filings held to 25 Aug 2026.